Platelet function tests for the monitoring of P2Y12 inhibitors

Bibliography

• Steinhubl SR, Berger PB, Mann JT III, Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288:2411-20
   PubMed Web of Science ®Google Scholar
• Mehta SR, Yusuf S, Peters RJ, Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527-33
   PubMed Web of Science ®Google Scholar
• Serebruany VL, Steinhubl SR, Berger PB, Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005;45:246-51
   PubMed Web of Science ®Google Scholar
• Elsenberg EH, van Werkum JW, van de Wal RM, The influence of clinical characteristics, laboratory and inflammatory markers on ‘high on-treatment platelet reactivity’ as measured with different platelet function tests. Thromb Haemost 2009;102:719-27
   PubMed Web of Science ®Google Scholar
• Pereillo JM, Maftouh M, Andrieu A, Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab Dispos 2002;30:1288-95
   PubMed Web of Science ®Google Scholar
• Savi P, Pereillo JM, Uzabiaga MF, Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 2000;84:891-6
   PubMed Web of Science ®Google Scholar
• Herbert JM, Savi P. P2Y12, a new platelet ADP receptor, target of clopidogrel. Semin Vasc Med 2003;3:113-22
   PubMedGoogle Scholar
• Matetzky S, Shenkman B, Guetta V, Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004;109:3171-5
   PubMed Web of Science ®Google Scholar
• Hochholzer W, Trenk D, Bestehorn HP, Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006;48:1742-50
   PubMed Web of Science ®Google Scholar
• Geisler T, Langer H, Wydymus M, Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 2006;27:2420-5
   PubMed Web of Science ®Google Scholar
• Buonamici P, Marcucci R, Migliorini A, Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007;49:2312-7
   PubMed Web of Science ®Google Scholar
• Frere C, Cuisset T, Quilici J, ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome [see comment]. Thromb Haemost 2007;98:838-43
   PubMed Web of Science ®Google Scholar
• Blindt R, Stellbrink K, de TA, The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis. Thromb Haemost 2007;98:1329-34
   PubMed Web of Science ®Google Scholar
• Bonello L, Paganelli F, rpin-Bornet M, Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. J Thromb Haemost 2007;5:1630-6
   PubMed Web of Science ®Google Scholar
• Price MJ, Endemann S, Gollapudi RR, Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation [see comment]. Eur Heart J 2008;29:992-1000
   PubMed Web of Science ®Google Scholar
• Marcucci R, Gori AM, Paniccia R, Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation 2009;119:237-42
   PubMed Web of Science ®Google Scholar
• Patti G, Nusca A, Mangiacapra F, Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study. J Am Coll Cardiol 2008;52:1128-33
   PubMed Web of Science ®Google Scholar
• Sibbing D, Braun S, Morath T, Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 2009;53:849-56
   PubMed Web of Science ®Google Scholar
• Breet NJ, Bouman HJ, van Werkum JW, Prospective comparison between platelet function tests in prediction of clinical outcomes in 1100 patients undergoing coronary stent placement: JAMA 2010:303:754-62
   PubMed Web of Science ®Google Scholar
• Siller-Matula J, Christ G, Lang IM, Multiple electrode aggregometry better predicts stent thrombosis than tha VASP. Thromb Haemost 2010;8(2):351-9
   Google Scholar
• Gurbel PA, Bliden KP, Guyer K, Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J Am Coll Cardiol 2005;46:1820-6
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Zaman KA, Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. Circulation 2005;111:1153-9
   PubMed Web of Science ®Google Scholar
• Bliden KP, Dichiara J, Tantry US, Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? J Am Coll Cardiol 2007;49:657-66
   PubMed Web of Science ®Google Scholar
• Cuisset T, Cayla G, Frere C, Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment? Eurointervention 2009;5:325-9
   PubMed Web of Science ®Google Scholar
• Bonello L, Camoin-Jau L, Arques S, Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol 2008;51:1404-11
   PubMed Web of Science ®Google Scholar
• Bonello L, Camoin-Jau L, Armero S, Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am J Cardiol 2009;103:5-10
   PubMed Web of Science ®Google Scholar
• van Werkum JW, Hackeng CM, Smit JJ, Monitoring antiplatelet therapy with point-of-care platelet function assays: a review of the evidence. Future Cardiol 2008;8:33-55
   Google Scholar
• Cuisset T, Cayla G, Frere C, Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment? Eurointervention 2009;5:325-9
   PubMed Web of Science ®Google Scholar
• van Werkum JW, Hackeng CM, de Korte FI, Point-of-care platelet function testing in patients undergoing PCI: between a rock and a hard place. Neth Heart J 2007;15:299-305
   PubMed Web of Science ®Google Scholar
• van Werkum JW, Kleibeuker M, Mieremet N, Evaluation of the platelet response to clopidogrel with light transmittance aggregometry: peak aggregation or late aggregation? J Thromb Haemost 2007;5:884-6
   PubMed Web of Science ®Google Scholar
• Bouman HJ, Parlak E, van Werkum JW, Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel. J Thromb Haemost 2010;8:482-8
   Google Scholar
• van Werkum JW, Harmsze AM, Elsenberg EH, The use of the VerifyNow system to monitor antiplatelet therapy: a review of the current evidence. Platelets 2008;19:479-88
   PubMed Web of Science ®Google Scholar
• van Werkum JW, van der Stelt CA, Seesing TH, A head-to-head comparison between the VerifyNowP2Y12-assay and light transmittance aggregometry for monitoring the individual platelet response to clopidogrel in patients undergoing elective PCI. J Thromb Haemost 2006;4:2516-18
   PubMed Web of Science ®Google Scholar
• Sibbing D, Braun S, Jawansky S, Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment. Thromb Haemost 2008;99:121-6
   PubMed Web of Science ®Google Scholar
• van Werkum JW, Kleibeuker M, Postma S, A comparison between the plateletworks assay and light transmittance aggregometry for monitoring the inhibitory effects of clopidogrel. Int J Cardiol 2008
   Web of Science ®Google Scholar
• Smit JJ, Ernst NM, Slingerland RJ, Platelet microaggregation inhibition in patients with acute myocardial infarction pretreated with tirofiban and relationship with angiographic and clinical outcome. Am Heart J 2006;151:1102-7
   PubMed Web of Science ®Google Scholar
• Favaloro EJ. Clinical application of the PFA-100. Curr Opin Hematol 2002;9:407-15
   PubMed Web of Science ®Google Scholar
• Pittens CA, Bouman HJ, van Werkum JW, Comparison between hirudin and citrate in monitoring the inhibitory effects of P2Y12 receptor antagonists with different platelet function tests. J Thromb Haemost 2009
   PubMed Web of Science ®Google Scholar
• Golanski J, Pluta J, Baraniak J, Watala C. Limited usefulness of the PFA-100 for the monitoring of ADP receptor antagonists-in vitro experience. Clin Chem Lab Med 2004;42:25-9
   PubMed Web of Science ®Google Scholar
• Chakroun T, Gerotziafas G, Robert F, In vitro aspirin resistance detected by PFA-100 closure time: pivotal role of plasma von Willebrand factor. Br J Haematol 2004;124:80-5
   PubMed Web of Science ®Google Scholar
• Schwarz UR, Geiger J, Walter U, Eigenthaler M. Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets-definition and detection of ticlopidine/clopidogrel effects. Thromb Haemost 1999;82:1145-52
   PubMed Web of Science ®Google Scholar
• Aleil B, Ravanat C, Cazenave JP, Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost 2005;3:85-92
   PubMed Web of Science ®Google Scholar
• van Werkum JW, van der Stelt CA, Seesing TH, The flow cytometric VASP assay can be used to determine the effectiveness of clopidogrel in patients treated with abciximab. J Thromb Haemost 2007;5:881-3
   PubMed Web of Science ®Google Scholar
• Aleil B, Meyer N, Cazenave JP, High stability of blood samples for flow cytometric analysis of VASP phosphorylation to measure the clopidogrel responsiveness in patients with coronary artery disease. Thromb Haemost 2005;94:886-7
   PubMed Web of Science ®Google Scholar
• Barragan P, Bouvier JL, Roquebert PO, Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv 2003;59:295-302
   PubMed Web of Science ®Google Scholar
• Varon D, Savion N. Impact cone and plate(let) analyzer. In: Michelson AD, editor, Platelets. 2nd edition. ISBN-10: 0-12-369367-5: Elsevier, 2006. p. 535-44
   Google Scholar
• Hartert H. Blutgerinnungsstudien mit der Thrombelastographie, einem neuen Untersuchungsverfahren. Klin Wochenscgr 1948;26:577-83
   PubMed Web of Science ®Google Scholar
• Tantry US, Bliden KP, Gurbel PA. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol 2005;46:1705-9
   PubMed Web of Science ®Google Scholar
• King SBIII, Smith SC Jr, 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. Circulation 2008;117:261-95
   PubMed Web of Science ®Google Scholar
• Agarwal S, Coakely M, Reddy K, Quantifying the effect of antiplatelet therapy: a comparison of the platelet function analyzer (PFA-100(R)) and modified thromboelastography (mTEG(R)) with light transmission platelet aggregometry. Anesthesiology 2006;105:676-83
   PubMed Web of Science ®Google Scholar
• von BN, Kastrati A, Wieczorek A, A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. Eur Heart J 2007;28:1814-19
   PubMed Web of Science ®Google Scholar
• Pena A, Collet JP, Hulot JS, Can we override clopidogrel resistance? Circulation 2009;119:2854-7
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, McCabe CH, Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15
   PubMed Web of Science ®Google Scholar
• Wallentin L, Becker RC, Budaj A, Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57
   PubMed Web of Science ®Google Scholar
• Cuisset T, Frere C, Quilici J, Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study [see comment]. Jacc: Cardiovasc Interv 2008;1:649-53
   PubMed Web of Science ®Google Scholar
• Valgimigli M, Campo G, de CN, Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study. Circulation 2009;119:3215-22
   PubMed Web of Science ®Google Scholar
• Cuisset T, Cayla G, Frere C, Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment? Eurointervention 2009;5:325-9
   PubMed Web of Science ®Google Scholar
• Sibbing D, Schulz S, Braun S, Antiplatelet Effects of Clopidogrel and Bleeding in Patients Undergoing Coronary Stent Placement. J Thromb Haemost 2010;8(2):250-6
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Becker RC, Mann KG, Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 2007;50:1822-34
   PubMed Web of Science ®Google Scholar
• Cuisset T, Frere C, Quilici J, High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes. Thromb Haemost 2007;97:282-7
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Tantry US. Effect of clopidogrel with and without eptifibatide on tumor necrosis factor-alpha and C-reactive protein release after elective stenting: results from the CLEAR PLATELETS 1b study. J Am Coll Cardiol 2006;48:2186-91
   PubMed Web of Science ®Google Scholar
• Fuchs I, Frossard M, Spiel A, Platelet function in patients with acute coronary syndrome (ACS) predicts recurrent ACS. J Thromb Haemost 2006;4(12):2547-52
   PubMed Web of Science ®Google Scholar